Impacting News- Prohost Biotech - Exclusive Biotech Research

Category: Impacting News

Pliant Therapeutics: Positive Long-Term Data from INTEGRIS-PSC Phase 2a Trial of Bexotegrast

Pliant Therapeutics Pliant Therapeutics is a late-stage biopharmaceutical company focusing on the discovery and development of novel therapeutics for the treatment of fibrotic diseases. Pliant's lead product candidate, bexotegrast ( PLN-74809 ), is an oral, small molecule, dual selective inhibitor...

July 16, 2024

Ionis Pharmaceuticals Announces Positive Detailed Results from the HALOS Study of ION582

Ionis Pharmaceuticals in the NEWS Yesterday, July 22, 2024, Ionis Pharmaceuticals ( IONS ) announced positive results from the completed multiple ascending dose ( MAD ) portion of the Phase 1/2 open-label study of ION582 in people with Angelman syndrome...

July 23, 2024

Viking Therapeutics Reports Promising News

Viking Therapeutics Viking Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders, with three compounds currently in clinical trials. Viking's research and development activities leverage...

July 25, 2024

Anavex Life Sciences: Phase IIb/III Trial Results of Blarcamesine Presented at Alzheimer's Association Conference

Anaves Life Sciences Trial Results of Blarcamesine Anavex Life Sciences ( AVXL ) presented comprehensive results from a Phase IIb/III study showing that blarcamesine (ANAVEX®2-73), once daily orally, significantly slowed clinical decline in people with early Alzheimer's disease ( AD...

July 29, 2024

Adaptimmune Therapeutics: A First Approved Treatment of Unresectable or Metastatic Synovial Sarcoma

Adaptimmune Therapeutics Adaptimmune Therapeutics plc ( ADAP ) announced that the U.S. FDA has accelerated the approval of TECELRA® for the treatment of adults with unresectable or metastatic synovial sarcoma who received prior chemotherapy, and are HLA-A*02:01P, -A*02:02P, -A*02:03P, or...

August 2, 2024

Exelixis Announces Q2 2024 Financial Results and Provides Corporate Update

Exelixis Q2 Results and Corporate Update Yesterday, Aug. 6, 2024, Exelixis, ( EXEL ) reported financial results for the second quarter of 2024, provided an update on progress toward achieving key corporate objectives, and detailed its recent and anticipated commercial,...

August 7, 2024

Cytokinetics Reports Management Update and Q2 2024 Financial Results

Cytokinetics Cytokinetics is a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing, and commercializing muscle biology-directed drug candidates as potential treatments for debilitating diseases in which cardiac muscle performance is compromised. The company is developing small-molecule drug candidates specifically...

August 12, 2024

Good News for Vertex Pharmaceuticals and for Crispr Therapeutics

Vertex Announces CASGEVY™ Reimbursement Agreement with NHS England Vertex Pharmaceuticals ( VRTX ) announced a reimbursement agreement with NHS England for eligible transfusion-dependent beta-thalassemia ( TDT ) patients to access the CRISPR/Cas9 gene-edited therapy, CASGEVY™ (exagamglogene autotemcel). The United Kingdom...

August 27, 2024

Regenxbio Announces Positive Results of its Product RGX-121 for Hunter Syndrome

Regenxbio Positive Results Regenxbio ( RGNX ) announced positive results from the Phase I/II/III CAMPSIITE® trial of RGX-121 for patients with Mucopolysaccharidosis Type 2 ( MPS II ), also known as Hunter syndrome. The results were presented at the Society...

September 5, 2024

Travere Therapeutics Announces Full FDA Approval of FILSPARI®

Travere Therapeutics Approval Travere Therapeutics, Inc., ( TVTX ) announced that the U.S. FDA has granted full approval to FILSPARI® (sparsentan) to slow kidney function decline in adults with primary IgAN who are at risk of disease progression. In February 2023, based...

September 11, 2024

Search ProhostBiotech

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis

September 19, 2024

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024